X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11554) 11554
Publication (658) 658
Newsletter (115) 115
Book Review (76) 76
Conference Proceeding (69) 69
Newspaper Article (53) 53
Dissertation (40) 40
Magazine Article (19) 19
Book Chapter (15) 15
Trade Publication Article (6) 6
Data Set (4) 4
Web Resource (4) 4
Paper (3) 3
Journal / eJournal (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
losartan (6934) 6934
male (5353) 5353
humans (4793) 4793
animals (4483) 4483
rats (3357) 3357
female (2860) 2860
losartan - pharmacology (2850) 2850
index medicus (2786) 2786
hypertension (2693) 2693
angiotensin receptor antagonists (2263) 2263
hypertension - drug therapy (2087) 2087
losartan - therapeutic use (2081) 2081
blood pressure - drug effects (2010) 2010
middle aged (1998) 1998
peripheral vascular disease (1896) 1896
pharmacology & pharmacy (1867) 1867
antihypertensive agents - therapeutic use (1750) 1750
angiotensin ii (1612) 1612
imidazoles - pharmacology (1581) 1581
angiotensin (1529) 1529
aged (1504) 1504
tetrazoles - pharmacology (1424) 1424
cardiac & cardiovascular systems (1321) 1321
antihypertensive agents - pharmacology (1320) 1320
adult (1261) 1261
blood-pressure (1238) 1238
rats, sprague-dawley (1231) 1231
angiotensin ii - pharmacology (1210) 1210
biphenyl compounds - pharmacology (1145) 1145
angiotensin ii type 1 receptor blockers - pharmacology (1115) 1115
hypertension - physiopathology (988) 988
treatment outcome (952) 952
blood pressure (943) 943
angiotensin ii type 1 receptor blockers - therapeutic use (926) 926
angiotensin-converting enzyme inhibitors - therapeutic use (912) 912
rats, wistar (871) 871
losartan - administration & dosage (831) 831
renin-angiotensin system (824) 824
physiology (823) 823
dose-response relationship, drug (813) 813
angiotensin-ii (804) 804
angiotensin ii - antagonists & inhibitors (787) 787
angiotensin ii - metabolism (776) 776
urology & nephrology (748) 748
renin-angiotensin system - drug effects (738) 738
mortality (708) 708
drug therapy, combination (703) 703
angiotensin-converting enzyme inhibitors - pharmacology (700) 700
receptor, angiotensin, type 1 (690) 690
expression (685) 685
end-point reduction (680) 680
losartan intervention (674) 674
tetrazoles - therapeutic use (673) 673
mice (658) 658
double-blind method (652) 652
time factors (632) 632
hypertension - complications (631) 631
captopril (627) 627
pyridines - pharmacology (611) 611
valsartan (601) 601
risk factors (598) 598
medicine, general & internal (592) 592
drug therapy (587) 587
antihypertensive agents - administration & dosage (558) 558
disease models, animal (554) 554
enalapril (539) 539
system (534) 534
heart-failure (528) 528
inhibition (518) 518
research (513) 513
hypertrophy (486) 486
receptor, angiotensin, type 2 (477) 477
receptors, angiotensin - metabolism (474) 474
rats, inbred shr (469) 469
receptor (467) 467
cells, cultured (451) 451
kidney - drug effects (451) 451
receptors (443) 443
receptor, angiotensin, type 1 - metabolism (438) 438
analysis (435) 435
angiotensin ii - physiology (435) 435
heart rate - drug effects (430) 430
antihypertensive agents - adverse effects (421) 421
physiological aspects (420) 420
heart failure (416) 416
renin-angiotensin system - physiology (412) 412
endocrinology & metabolism (407) 407
in vitro techniques (407) 407
rat (406) 406
irbesartan (403) 403
hydrochlorothiazide (402) 402
biphenyl compounds - therapeutic use (401) 401
disease (399) 399
oxidative stress (399) 399
losartan potassium (392) 392
renin (388) 388
losartan - adverse effects (386) 386
medicine, research & experimental (381) 381
heart failure - drug therapy (365) 365
blood pressure - physiology (363) 363
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10957) 10957
Russian (159) 159
German (132) 132
Spanish (121) 121
Chinese (120) 120
Japanese (94) 94
French (64) 64
Portuguese (30) 30
Italian (29) 29
Korean (15) 15
Polish (15) 15
Danish (13) 13
Turkish (11) 11
Swedish (9) 9
Czech (8) 8
Hungarian (7) 7
Ukrainian (6) 6
Dutch (4) 4
Norwegian (4) 4
Persian (4) 4
Slovak (4) 4
Croatian (3) 3
Serbian (3) 3
Hebrew (2) 2
Indonesian (2) 2
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


A High-Performance Liquid Chromatographic Assay for the Determination of Losartan in Plasma, 12/2003
A rapid and sensitive HPLC method was developed for determination of losartan in plasma. Losartan was extracted from plasma by a two-step extraction procedure... 
Losartan, Plasma, Extraction, HPLC analysis
Journal
The New England Journal of Medicine, ISSN 0028-4793, 07/2009, Volume 361, Issue 1, pp. 40 - 51
This study aimed to determine whether early administration of drugs that block the renin–angiotensin system slows the progression of change in glomerular... 
CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | STRUCTURAL-FUNCTIONAL RELATIONSHIPS | CORTICAL INTERSTITIUM | BLOOD-PRESSURE CONTROL | EARLY NATURAL-HISTORY | RETINOPATHY | ANGIOTENSIN-CONVERTING ENZYME | NEPHROPATHY | PROGRESSION | ENDOTHELIAL GROWTH-FACTOR | Retina - drug effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Male | Albuminuria | Angiotensin II Type 1 Receptor Blockers - pharmacology | Enalapril - therapeutic use | Enalapril - adverse effects | Mesangial Cells - drug effects | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Diabetic Nephropathies - prevention & control | Double-Blind Method | Diabetes Mellitus, Type 1 - physiopathology | Kidney Glomerulus - drug effects | Diabetes Mellitus, Type 1 - pathology | Kaplan-Meier Estimate | Losartan - pharmacology | Logistic Models | Kidney Glomerulus - pathology | Disease Progression | Diabetes Mellitus, Type 1 - drug therapy | Diabetic Retinopathy - prevention & control | Enalapril - pharmacology | Losartan - therapeutic use | Mesangial Cells - pathology | Losartan - adverse effects | Renin-Angiotensin System - drug effects | Retina - pathology | Diabetic retinopathy | Control | Usage | Enalapril | Type 1 diabetes | Patient outcomes | Losartan | Enalaprilat | Drug therapy | Kidneys | Diabetes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
07/2013
Purpose: To develop a new spectrophotometric method for the analysis of losartan potassium in pharmaceutical formulations by making its complex with copper.... 
Validation | Losartan | Copper complex | Spectrophotometry
Web Resource
ORIGINAL ARTICLE - COMPARATIVE EFFECTS OF LOSARTAN AND ENALAPRIL ON SERUM DIGOXIN LEVELS IN PATIENTS WITH CONGESTIVE HEART FAILURE, 07/2004
The aim of this study was to investigate the effect of AT1-receptor antagonist, losartan usage in place of angiotensin converting enzyme (ACE) inhibitor,... 
Medicine | Digoxin, enalapril, losartan, pharmacokinetics. gm04025
Journal
Analytica Chimica Acta, ISSN 0003-2670, 06/2018, Volume 1010, pp. 76 - 85
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 22, pp. 2061 - 2071
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 23, pp. 2433 - 2446
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2011, Volume 108, Issue 7, pp. 2909 - 2914
The dense collagen network in tumors significantly reduces the penetration and efficacy of nanotherapeutics. We tested whether losartan—a clinically approved... 
Nanoparticles | Receptors | Medical treatment | Collagens | Antineoplastics | Viruses | Dosage | Pancreatic neoplasms | Tumors | Cancer | Thrombospondin-1 | Drug delivery | Transport | Transforming growth factor β | Matrix modifier | INTERSTITIAL FLUID PRESSURE | SOLID TUMORS | transforming growth factor beta | MULTIDISCIPLINARY SCIENCES | PANCREATIC-CANCER | drug delivery | transport | BLOOD-FLOW | ANGIOTENSIN | CONVERTING-ENZYME-INHIBITORS | GROWTH-FACTOR-BETA | MOUSE MODEL | TYPE-1 RECEPTOR BLOCKADE | thrombospondin-1 | RENAL INJURY | matrix modifier | Immunohistochemistry | Skin Neoplasms - drug therapy | Fluorescence Recovery After Photobleaching | Humans | DNA Primers - genetics | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Doxorubicin - analogs & derivatives | Polymerase Chain Reaction | Female | Collagen - biosynthesis | Losartan - pharmacokinetics | Doxorubicin - administration & dosage | Carcinoma - drug therapy | Nanotechnology - methods | Losartan - pharmacology | Mice, SCID | Breast Neoplasms - drug therapy | Polyethylene Glycols - administration & dosage | Oncolytic Virotherapy - methods | Simplexvirus | Animals | Analysis of Variance | Mice | Drug Delivery Systems - methods | Drugs | Care and treatment | Drug delivery systems | Medical technology | Research | Properties | Vehicles | Medical laboratory technology | Collagen | Losartan | Nanotechnology | Proteins | Nanoscience | Pharmacology | Drug therapy | Protein synthesis | Biological Sciences | Physical Sciences | transforming growth factor β
Journal Article